Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8774154 | 0.95 | EGLN1 (0.47) | EGLN1FFAR1CYP2A6ACACBGRM5 | |
| SCHEMBL8774819 | 0.89 | FFAR1 (0.43) | EGLN1FFAR1ACACB | |
| SCHEMBL8774460 | 0.86 | HSD17B10 (0.43) | FFAR1 | |
| SCHEMBL8775133 | 0.85 | HSD17B10 (0.49) | FFAR1MTOR | |
| SCHEMBL8774897 | 0.84 | FFAR1 (0.45) | EGLN1FFAR1ACACBGRM5 | |
| SCHEMBL8774677 | 0.81 | FFAR1 (0.43) | EGLN1FFAR1ACACB | |
| SCHEMBL8774747 | 0.81 | EGLN1 (0.42) | EGLN1GRM5METAP2 | |
| SCHEMBL8775015 | 0.81 | EGLN1 (0.42) | EGLN1GRM5METAP2 | |
| SCHEMBL9154247 | 0.80 | GRM5 (0.47) | EGLN1FFAR1CYP2A6ACACBGRM5 | |
| SCHEMBL9508806 | 0.80 | GRM5 (0.41) | EGLN1FFAR1CYP2A6ACACBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0519370-B1 | Heterocyclic derivatives | MERCK PATENT GMBH (DE) | 1997-11-05 | — | — | EP | disclosed |
| EP-0519370-A2 | Heterocyclic derivatives | MERCK PATENT GmbH (DE) | 1992-12-23 | — | — | EP | disclosed |